Filtered By:
Specialty: Hematology
Therapy: Stem Cell Therapy

This page shows you your search results in order of relevance. This is page number 14.

Order by Relevance | Date

Total 242 results found since Jan 2013.

Organ function indications and potential improvements following curative therapy for sickle cell disease
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):277-282. doi: 10.1182/hematology.2022000372.ABSTRACTCurative therapies for sickle cell disease include allogeneic hematopoietic stem cell transplantation (HSCT) and gene-modified autologous stem cell transplantation. HSCT has been used for 30 years with success measured by engraftment, symptom control, graft-vs-host disease (GVHD) risk, organ toxicity, and immune reconstitution. While human leukocyte antigen-matched sibling donor (MSD) transplants have excellent outcomes, alternate donor transplants (unrelated/haploidentical) are just beginning to overcome GVHD and...
Source: Hematology ASH Education Program - December 9, 2022 Category: Hematology Authors: Monica L Hulbert Allison A King Shalini Shenoy Source Type: research

Long-Term Outcome and Evaluation of Organ Function in Pediatric Patients Undergoing Haploidentical and Matched Related Hematopoietic Cell Transplantation for Sickle Cell Disease
We report the long-term outcomes of 22 pediatric patients who underwent related donor HSCT for SCD at St. Jude Children's Research Hospital, either a myeloablative sibling MRD HSCT (n = 14) or reduced-intensity parental haploidentical donor HSCT (n = 8). The median patient age was 11.0 ± 3.9 years in the MRD graft recipients and 9.0 ± 5.0 years in the haploidentical donor graft recipients. The median follow-up was 9.0 ± 2.3 years, with an overall survival (OS) of 93% and a recurrence/graft failure rate of 0%, for the MRD cohort and 7.4 ± 2.4 years, with an OS of 75%, disease-free survival of 38%, and disease recurren...
Source: Biology of Blood and Marrow Transplantation - February 18, 2013 Category: Hematology Authors: Mari H. Dallas, Brandon Triplett, David R. Shook, Christine Hartford, Ashok Srinivasan, Joseph Laver, Russell Ware, Wing Leung Tags: Clinical Research Source Type: research

Allogeneic bone marrow mesenchymal stem cells transplantation for stabilizing and repairing of atherosclerotic ruptured plaque
Abstract: Introduction: There have been no satisfactory therapies on stabilizing and repairing ruptured plagues nowadays, which are the fundamental causes of acute coronary syndrome (ACS) and stroke. The aim of this study was to investigate the therapeutic potential of bone marrow mesenchymal stem cells (MSCs) in stabilizing and repairing ruptured plaques.Materials and Methods: 28 male New Zealand rabbits were randomly divided into 2 groups after establishment of atherosclerotic disrupted plaque model by liquid nitrogen frostbite: MSCs transplantation group and control group. MSCs were isolated, cultured in vitro, and labe...
Source: Thrombosis Research - April 25, 2013 Category: Hematology Authors: Shun-Miao Fang, Da-Yong Du, Yun-Tian Li, Xing-Li Ge, Peng-Tao Qin, Qing-Hua Zhang, Yang Liu Tags: Platelets and Cell Biology Source Type: research

Sickle cell disease: time for a closer look at treatment options?
Summary Tremendous progress has been made in the care of individuals with sickle cell over the past several decades. Major successes have been comprehensive infection prophylaxis, prediction and prevention of stroke, and better transfusion care, the latter including both prevention of alloimmunization and treatment of iron overload. However, definitive therapies remain limited to hydroxycarbamide (hydroxyurea) and stem cell transplantation, both of which have been in use for at least two decades. Despite knowing the progressive natural history of the disease with organ dysfunction, failure, and ultimately death at a young ...
Source: British Journal of Haematology - June 15, 2013 Category: Hematology Authors: Sujit Sheth, Maureen Licursi, Monica Bhatia Tags: Review Source Type: research

Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation
In conclusion, SAEs after donation are rare but more often occurred in BM donors and women. In addition, there was no evidence of increased risk for cancer, autoimmune illness, and stroke in donors receiving granulocyte colony-stimulating factor during this period of observation.
Source: Blood - June 5, 2014 Category: Hematology Authors: Pulsipher, M. A., Chitphakdithai, P., Logan, B. R., Navarro, W. H., Levine, J. E., Miller, J. P., Shaw, B. E., O'Donnell, P. V., Majhail, N. S., Confer, D. L. Tags: Transfusion Medicine, Transplantation Source Type: research

Hematopoietic Stem Cell Transplantation for Sickle Cell Disease: State of the Science
This article is protected by copyright. All rights reserved.
Source: European Journal of Haematology - September 1, 2014 Category: Hematology Authors: Julie‐An Talano, Mitchell S. Cairo Tags: Review Article Source Type: research

Smoothing the crescent curve: sickle cell disease.
Authors: Talano JA, Cairo MS Abstract Sickle cell disease (SCD) is an inherited disorder secondary to a point mutation at the sixth position of the beta chain of human hemoglobin that results in the replacement of valine for glutamic acid. This recessive genetic abnormality precipitates the polymerization of the deoxygenated form of hemoglobin S that induces a major distortion of red blood cells (sickle red blood cells), which decreases sickle red blood cell deformability, leading to chronic hemolysis and vasoocclusion. These processes can result in severe complications, including chronic pain, end organ dysfunctio...
Source: Hematology ASH Education Program - February 20, 2015 Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research

How I treat and manage strokes in sickle cell disease
Neurologic complications are a major cause of morbidity and mortality in sickle cell disease (SCD). In children with sickle cell anemia, routine use of transcranial Doppler screening, coupled with regular blood transfusion therapy, has decreased the prevalence of overt stroke from ~11% to 1%. Limited evidence is available to guide acute and chronic management of individuals with SCD and strokes. Current management strategies are based primarily on single arm clinical trials and observational studies, coupled with principles of neurology and hematology. Initial management of a focal neurologic deficit includes evaluation by...
Source: Blood - May 28, 2015 Category: Hematology Authors: Kassim, A. A., Galadanci, N. A., Pruthi, S., DeBaun, M. R. Tags: Sickle Cell Disease, How I Treat, Free Research Articles, Red Cells, Iron, and Erythropoiesis, Clinical Trials and Observations Source Type: research

Central Nervous System Complications and Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation
This retrospective study of 351 patients, who have undergone allogeneic hematopoietic stem cell transplantation between 2002 and 2011 at the University of Nebraska Medical Center, demonstrated 12% incidence of central nervous system complications. The most common complications included posterior reversible encephalopathy syndrome (40%), stroke or transient ischemic attack (24%), seizures (20%), and infection (9%). The 5-year overall survival was significantly lower among patients with versus without central nervous system complications (14% vs. 44%, p=0.0004).
Source: Clinical Lymphoma, Myeloma and Leukemia - June 18, 2015 Category: Hematology Authors: Vijaya Raj Bhatt, Vamshi Balasetti, Jagar J. Abduall, Smith Giri, James O. Armitage, Fausto R. Loberiza, R. Gregory Bociek, Philip J. Bierman, Lori J. Maness, Julie M. Vose, Pierre Fayad, Mojtaba Akhtari Source Type: research

Stem cell mobilisation by granulocyte-colony stimulating factor in patients with acute myocardial infarction. Long-term results of the REVIVAL-2 trial.
In conclusion, these long-term follow-up data show that G-CSF does not improve clinical outcomes of patients with acute myocardial infarction. PMID: 26790705 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - January 21, 2016 Category: Hematology Authors: Steppich B, Hadamitzky M, Ibrahim T, Groha P, Schunkert H, Laugwitz KL, Kastrati A, Ott I, Regenerate Vital Myocardium by Vigorous Activation of Bone Marrow Stem Cells (REVIVAL-2) Study Investigators Tags: Thromb Haemost Source Type: research

Mesenchymal stem/stromal cell‐derived extracellular vesicles as a new approach in stem cell therapy
Mesenchymal stem or stromal cells (MSCs) are widely applied in regenerative and immune modulating therapies. Initially, it was assumed that administered MSCs integrate into damaged tissues to exert their clinical functions. However, in recent years accumulating evidence has been provided that MSCs rather act in a paracrine than a cellular manner. To this end, extracellular vesicles (EVs), which are secreted by MSCs in vivo and in vitro, seem to exert the MSCs’ therapeutic effects. So far, MSC‐EVs have been shown to improve functional recoveries following ischemic events, such as stroke and myocardial infarction, and to...
Source: ISBT Science Series - January 29, 2016 Category: Hematology Authors: V. Börger, M. Bremer, A. Görgens, B. Giebel Tags: Invited Review Source Type: research

Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial
This study is registered with clinicaltrials.gov registry, number NCT00799513. Findings Between March 24, 2009, and Dec 22, 2015, we recruited 48 patients. 46 of 48 enrolled patients were assessable (two patients had unconfirmed diagnoses). 36 (78%) of 46 patients had de novo DLBCL and ten (22%) of 46 patients had transformed DLBCL. At a median follow-up of 25 months (IQR 12–56), 556 lenalidomide courses had been delivered, with an average mean of 12 courses (range 3–41) per patient; 19 patients were still in treatment at a median follow-up of 25 months. Lenalidomide was well tolerated; with the exception of neutropeni...
Source: The Lancet Haematology - February 16, 2017 Category: Hematology Source Type: research